Lipoxins A₄ and B₄ inhibit glial cell activation via CXCR3 signaling in acute retinal neuroinflammation.

"Declarations Ethics approval and consent to participateAll animal procedures and protocols conformed to the guidelines of the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research, and were approved by the University Health Network Animal Care and Use Committee in accordance with relevant Canadian guidelines and regulations. Competing interestsSeveral authors (I. L-B, J.M.S., K.G.) have obtained a US patent for use of lipoxins to treat neurodegeneration. Competing interests Several authors (I. L-B, J.M.S., K.G.) have obtained a US patent for use of lipoxins to treat neurodegeneration."

"Funding This work was supported by, CIHR Grants PJT166201 (JMS) and PJT168845 (JMS), and NIH Grant R01EY030218 (JMS & KG). JMS holds the Graham Trope Glaucoma Research Chair."